Rapid Micro Biosystems to Present at 43ʳᵈ Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Rapid Micro Biosystems (Nasdaq: RPID) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company, which specializes in providing mission critical automation solutions for healthcare product manufacturing, will deliver its presentation on Thursday, January 16, 2025, at 12:45 p.m. Eastern Time (9:45 a.m. Pacific Time).
Interested parties can access a live webcast of the presentation through the company's investor relations website at investors.rapidmicrobio.com. The presentation will also be archived and available for replay following the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, RPID declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference.
The Company is scheduled to present on Thursday, January 16, 2025, at 12:45 p.m. Eastern Time (9:45 a.m. Pacific Time). A live webcast of the presentation will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.
FAQ
When is RPID presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch RPID's J.P. Morgan Healthcare Conference presentation?
What is the focus of Rapid Micro Biosystems' (RPID) business?
Which annual healthcare conference is RPID participating in for 2025?
